SCHEMBL6790784

SCHEMBL6790784

CC(C)(C)OC(=O)N(CCc1ccccn1)c1ccc(NC(=O)c2ccccc2-c2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
RXFP1 Q9HBX9 2/20 0.43
HTT P42858 2/20 0.43
ALDH1A1 P00352 1/20 0.43
SMO Q99835 2/20 0.40
ABCG2 Q9UNQ0 2/20 0.40
POLB P06746 2/20 0.39
AURKA O14965 2/20 0.38
KDR P35968 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
LMNA P02545 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
SLC11A2 P49281 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6792911 0.90 SMO (0.47) HTTALDH1A1SMOPOLBKDR
SCHEMBL6795007 0.90 SMO (0.48) HTTALDH1A1SMOPOLBLMNA
SCHEMBL6799630 0.90 SMO (0.42) KMT2ANPC1RAB9ASMN1; SMN2HTT
SCHEMBL6793636 0.90 SMO (0.42) RAB9ASMN1; SMN2HTTALDH1A1SMO
SCHEMBL6791610 0.90 SMO (0.42) NPC1RAB9AMAPTSMN1; SMN2HTT
SCHEMBL6793251 0.90 SMO (0.42) HTTALDH1A1SMOPOLBLMNA
SCHEMBL6788937 0.89 SMO (0.42) MEN1KMT2ANPC1RAB9AHTT
SCHEMBL6800714 0.89 SMO (0.42) SMN1; SMN2HTTALDH1A1SMOPOLB
SCHEMBL6795221 0.89 CNR1 (0.43) NPC1RAB9ASMN1; SMN2HTTALDH1A1
SCHEMBL6791168 0.89 SMO (0.42) KMT2AMAPTRXFP1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 MEN1 2426/4885KMT2A 2457/4885NPC1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.